Continuous glucose monitoring in cystic fibrosis – A practical guide

Christine L. Chan, Katie Larson Ode, Andrea Granados, Amir Moheet, Antoinette Moran, Shihab Hameed

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Our ability to monitor blood glucose levels has become increasingly accurate over the last few decades. Continuous glucose monitoring (CGM) technology now allows providers and patients the ability to monitor glucose levels retrospectively as well as in real-time for diabetes management. CGM also provides the ability to study glucose patterns and trends for insight into the pathophysiology and natural history of disease. CGM captures a more complete picture of glucose profiles than traditional measures of glycemia such as the hemoglobin A1c or self-monitoring of blood glucose levels. This article provides a review of the history of glucose monitoring, a review of the literature pertaining to CGM with a focus on studies in patients with cystic fibrosis, and discusses practical uses of CGM technology and its application for the evaluation and management of cystic fibrosis related diabetes.

Original languageEnglish (US)
Pages (from-to)S25-S31
JournalJournal of Cystic Fibrosis
Volume18
DOIs
StatePublished - Oct 2019

Bibliographical note

Funding Information:
CLC, KLO, AG, AM, and AM receive grant support through the Cystic Fibrosis Foundation, Emerging Leaders in CF Endocrinology (EnVision) Program. Additionally, CLC is supported by the Cystic Fibrosis Foundation grant CHAN16A0 and receives industry support from Insulet and Dexcom . AG is supported by Washington University Institute of Clinical & Translational Sciences ( ICTS ) KL2 Career Development Awards Program KL2TR002346-02 . SH is grateful for funding assistance from the National Health and Medical Research Council of Australia , the Australasian Cystic Fibrosis Research Trust , Regional Diabetes Support Scheme , Sydney Children's Hospital Foundation , Australasian Pediatric Endocrine Care Grant from Pfizer , and for Industry support from Novo Nordisk , Medtronic , Abbott Diagnostics .

Funding Information:
CLC, KLO, AG, AM, and AM receive grant support through the Cystic Fibrosis Foundation, Emerging Leaders in CF Endocrinology (EnVision) Program. Additionally, CLC is supported by the Cystic Fibrosis Foundation grant CHAN16A0 and receives industry support from Insulet and Dexcom. AG is supported by Washington University Institute of Clinical & Translational Sciences (ICTS) KL2 Career Development Awards Program KL2TR002346-02. SH is grateful for funding assistance from the National Health and Medical Research Council of Australia, the Australasian Cystic Fibrosis Research Trust, Regional Diabetes Support Scheme, Sydney Children's Hospital Foundation, Australasian Pediatric Endocrine Care Grant from Pfizer, and for Industry support from Novo Nordisk, Medtronic, Abbott Diagnostics.The authors would like to thank the Cystic Fibrosis Foundation and faculty mentors from the EnVision: Emerging Leaders in CF Endocrinology Program for their ongoing support and mentorship of the program awardees.

Publisher Copyright:
© 2019 European Cystic Fibrosis Society

Keywords

  • Artificial pancreas
  • Continuous glucose monitoring
  • Cystic fibrosis related diabetes

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Continuous glucose monitoring in cystic fibrosis – A practical guide'. Together they form a unique fingerprint.

Cite this